Barclays’s Marker Therapeutics MRKR Stock Holding History
Bought
Maintained
Sold
Other funds holding MRKR
Barclays's MRKR Position: Q3 2026 in Review
Barclays sold out of Marker Therapeutics (MRKR) in Q3 2026, closing a stake of 63 shares — an estimated $93 sold.
Barclays first reported a position in MRKR in Q2 2018 and held it in 9 quarters. The position peaked at $889K in Q4 2018. 36 funds tracked by Wall St. Rank hold MRKR as of Q3 2026.
- Barclays reported no remaining Marker Therapeutics position as of Q3 2026 after selling out during the quarter.
- Barclays sold 63 Marker Therapeutics shares in Q3 2026, an estimated $93.
- Barclays first reported a position in Marker Therapeutics in Q2 2018 and held it in 9 quarters.
- Barclays's Marker Therapeutics position peaked at $889K in Q4 2018.
- 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.